Heavy Static At Danaher Corporation

Weak results in test & measurement and frustration over a lack of big M&A weighs on the shares

Jul 18, 2014 at 5:45PM

"What we've got here is ... failure to communicate," Cool Hand Luke.

As one of the best-loved conglomerates out there (and seldom a cheap stock as a result), Danaher (NYSE:DHR) operates to a different set of Wall Street expectations than most companies. In the case of second quarter earnings and forward guidance, disappointing results in the volatile test & measurement business not only sent the stock down but will likely renew calls for management to consider breaking up the company. Perhaps adding a bit of irony to that, analysts also continue to express frustration that Danaher isn't making bigger splashes with its M&A efforts.

Danaher is Danaher, and the company will be fine. The diagnostics business is getting stronger and operations like water quality/treatment have strong growth potential in markets like China and India. Though I can't say that the shares have reached a bargain price yet, this may be a name to add to the watchlist in case the disappointment coming out of this quarter leads to a more pronounced skid.

Barely missing the mark in Q2
It seems as though there is a lot more concern about what went wrong for Danaher in the second quarter than what went right. All told, revenue revenue rose 5% as reported (3% on an organic basis) and just barely missed the average estimate and likewise the 5%-plus growth in operating income was just slightly below expectations.

Test & Measurement was the problem child this quarter, with sales down 2% on an organic basis. Dental grew 2% organically, while Environmental and Industrial Tech were both up 3.5% (which Motion seeing its first positive quarter in about two years). Life Sciences and Diagnostics was the leader, with organic growth of 6% on strong performance at Beckman and good results from the IRIS business.

Segment-level profits rose 4%, with Test & Measurement giving a particularly bad showing (down almost 12%) while LSD was up more than 17%. A bit concerning was that only LSD and Industrial Tech showed segment-level margin improvements.

Flunking the test, for now...
The problems in Test & Measurement come down to weak spending by wireless network operators, and Danaher management expects this to continue into 2015. Volatile spending from carriers is nothing particularly new and it underlines part of the reason Agilent is splitting off its test & measurement operations (Keysight) from the life sciences operations. Danaher's news is not particularly positive for EXFO, Teledyne, or Agilent, but Agilent/Keysight at least as the advantage of a more diverse collection of businesses and end market exposures.

Waiting for deals, while getting deals
It has been a while now since Danaher has launched a major acquisition and the analysts who follow Danaher seem to be getting edgy about it. Satisfying sell-side analysts who are jonesing for some activity is a poor reason to do deals, though, and Danaher has echoed a lament that has been expressed by other conglomerates like Dover and Parker Hannifin – namely, that deal valuations have risen significantly and there aren't a lot of attractively priced assets out there right now.

It's also not as though Danaher has just been sitting still. The company has concluded 10 deals for over $1 billion this year. Most recently, the company agreed to acquire Siemens' Microbiology business for $450 million. Danaher paid about 2.25x sales for a business with good margins and one that should represent a good opportunity for synergies with Beckman and the life sciences operations (particularly with an opportunity to follow Bruker and bioMerieux into MALDI-TOF in clinical microbiology).

Should Danaher play to its strengths in health?
Life sciences and diagnostics now represent more than a third of Danaher's revenue and adding in the Dental operations brings the total health/life sciences exposure closer to 50%. Danaher has done a fine job of turning around Beckman and the sales growth has caught up to Abbott Labs. Prolonged weakness at Siemens and Johnson & Johnson (before the sale) didn't hurt Danaher's efforts and with sales growing nicely again there should be more opportunities to boost margins (which are almost 300bp below the company segment average).

The question I have is whether Danaher wants to do more. Danaher management has generally tried to run a balanced operation, so I would frankly expect acquisitions to be anywhere but health and life sciences. Motion and motion control, industrial sensors/controls, and product ID all seem like places where Danaher could expand – perhaps even going so far as to consider acquiring a company like Rockwell Automation. On the other hand, buying more of Siemens' flagging diagnostics operations could be another turnaround opportunity akin to Beckman and a chance to grow a business serving a market with good long-term growth and margins.

The bottom line
I still expect Danaher to generate long-term free cash flow in the mid single or "mid high" single digits and that sort of growth suggests the shares are close to fair value. I'd much prefer to buy Danaher at a price below fair value, but that opportunity comes very rarely. Given the weakness in test & measuremnt and management's commitment to maintaining value discipline, I could see these shares lagging over the next couple of quarters and that could create an interesting long-term opportunity. With that, I'd definitely keep Danaher on a watch list.

A huge long-term opportunity for your portfolio
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers